Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality dis- order, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- context label "Adults" assertion.
- association label "First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics" assertion.
- DB00246 label "Ziprasidone" assertion.
- DB00246 label "Ziprasidone" assertion.
- DB00246 label "Ziprasidone" assertion.
- DB00246 label "Ziprasidone" assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- DB00996 label "Gabapentin" assertion.
- DB00996 label "Gabapentin" assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- association label "Citicoline was well tolerated but did not reduce alcohol consump- tion compared with placebo as measured by the time line follow back-method. The authors conclude that although citicoline has shown promise on many fields, it did not prove beneficial in treating AUD in these patients" assertion.
- DB12153 label "Citicoline" assertion.
- context label "Adults" assertion.
- association label "The purpose of this review is to summarize the current evidence of the off-label use of intravenous (IV) olanzapine and discuss its risks versus benefits for the management of agitation." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- DB01149 label "Nefazodone" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- association label "A 30-year-old insomniac, an off-label user of quetiapine, presented with blurring of central vision, eventually diagnosed as central serous chorioretinopathy." assertion.
- context label "Adults" assertion.
- association label "Among those drugs, modafinil (MOD) and its ( R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clinical trials psychostimulant use disorder" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." assertion.
- context label "adults" assertion.
- association label "Guidelines recommend the use of neuromodulators in patients with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics; however, there is a lack of data from randomised controlled trials supporting their use." assertion.
- context label "adults" assertion.
- association label "Ketamine is not yet approved by regulatory agencies, but is widely used off‐label by private so‐called ketamine clinics." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "Children and adolescents" assertion.
- association label "The use of selective serotonin reuptake inhibitors (SSRIs) like citalopram in the clinical treatment of depressive symptoms in children and adolescents has become increasingly common, although application is mostly off-label." assertion.
- context label "adults" assertion.
- association label "Two other sedating antidepressants, mirtazapine and trimipramine, are commonly used off-label for the treatment of ID without clear recommendations by any of the guidelines." assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- context label "adults" assertion.
- association label "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]" assertion.
- context label "adults" assertion.
- association label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "It has been tested in multiple clinical trials since it could be promising in AUD treatment. Topiramate decreases reinforcing effects of alcohol and craving. A meta-analysis, based on data from seven random studies (2003-2014), suggested that topiramate might have beneficial effects in AUD treatment but because of its many side effects, the use is limited. The most common side effects are cognitive dysfunction, paresthesia, and taste abnormalities." assertion.
- context label "adults" assertion.
- association label "While alcohol induces an increase of dopamine, ondansetron reduces the release of the neurotransmitter by blocking the 5-HT3 receptors. Several studies investigated the effectiveness of ondansetron by dividing alcoholic individuals into two subgroups based on their genotype for the promoter region of the SLC6A4 gene coding for the serotonin transporter (5-HTTLPR L/S polymorphism). The study showed that the patients with the LL genotype treated with ondansetron responded better in terms of alcohol amount and days of abstinence, compared to the other subgroups. Based on these results, researchers have further investigated genotype LL carriers, by analyzing the role of a functional polymorphism of the SLC6A4 gene (rs1042173 [T/G] SNP). The result was that individuals who carry both 5-HTTLPR LL polymorphism and rs1042173 TT polymorphism, treated with ondansetron at the dosage of 0.5 mg/die, present a more effective response to the drug. Unfortunately, the sample of this exploratory study was too small to be validated." assertion.
- DB00904 label "Ondansetron" assertion.
- DB00904 label "Ondansetron" assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "Adults" assertion.
- association label "Pitolisant and sodium oxybate show promising results in two retrospective studies. The efficacy of γ-aminobutyric acid-A receptor antagonists on objective EDS needs to be clarified. All these medications are used off-label for the management of EDS in IH." assertion.
- DB09072 label "Sodium Oxybate" assertion.
- DB01018 label "Guanfacine" assertion.
- DB00264 label "metoprolol" assertion.
- DB00624 label "Transdermal testosterone" assertion.
- DB00594 label "Amiloride" assertion.
- DB00722 label "lisinopril" assertion.
- DB00335 label "atenolol" assertion.
- DB01104 label "Sertraline" assertion.
- DB01104 label "Sertraline" assertion.
- DB01104 label "Sertraline" assertion.
- DB01104 label "sertraline" assertion.
- DB01197 label "captopril" assertion.
- DB00457 label "Prazosin" assertion.